Zaloguj Zarejestruj się zadarmo

AC Immune SA organizacji Wskaźnik krótkiej sprzedaży

Jaka jest wartość Wskaźnik krótkiej sprzedaży organizacji AC Immune SA?

Wartość Wskaźnik krótkiej sprzedaży organizacji AC Immune SA to 5.80

Jaka jest definicja Wskaźnik krótkiej sprzedaży?



Wskaźnik krótkiej sprzedaży (Short ratio) to liczba akcji sprzedanych na krótko podzielona przez średnią wartość dzienną.

Short ratio is calculated by dividing the number of shares sold short by the average daily trading volume, generally over the last 30 trading days. The ratio represents the number of days it takes short sellers on average to repurchase all the borrowed shares. The ratio is used by both fundamental and technical traders to identify trends.

The percentage represents the number of days it takes short sellers on average to repurchase all the borrowed shares. Short selling is the practice of selling securities or other financial instruments that are not currently owned, and subsequently repurchasing them. In the event of an interim price decline, the short seller profits, since the cost of (re)purchase is less than the proceeds received upon the initial (short) sale. Conversely, the short position closes out at a loss if the price of a shorted instrument rises prior to repurchase. A high short ratio can be an indicator that there will be some buying pressure on the security that would increase its price.

Wskaźnik krótkiej sprzedaży firm w Health Care sektor na NASDAQ w porównaniu do AC Immune SA

Czym się zajmuję organizacja AC Immune SA?

ac immune is a clinical-stage swiss-based biopharmaceutical company, listed on nasdaq, which aims to become a global leader in precision medicine for neurodegenerative diseases. the company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases caused by misfolding proteins. ac immune’s two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as alzheimer’s disease (ad). the company’s pipeline features nine therapeutic and three diagnostic product candidates – with five product candidates currently in clinical trials. the most advanced of these is crenezumab, a humanized anti-amyloid-β monoclonal igg4 antibody that targets monomeric and aggregated forms of amyloid-β, with highest affinity for neurotoxic oligomers. crenezumab is currently in two phase 3 clinical studies for ad, under a global program conducted by the collabor

Firmy z wskaźnik krótkiej sprzedaży podobne do AC Immune SA